The United States Patent and Trademark Office (USPTO) has granted patent US12582810B2 to Biograil ApS for a novel delivery device. This device is designed for the oral delivery of drug substances, with a specific focus on their administration to internal surfaces, including the gastrointestinal tract. The patent abstract highlights its utility for delivering active drug substances, particularly those with low permeability.

This patent grant signifies a new intellectual property asset for Biograil ApS in the medical device and pharmaceutical sector. While this is a patent grant and not a regulatory rule, it may inform future product development and regulatory submissions for oral drug delivery systems. Companies operating in this space should be aware of this granted patent as it pertains to their own research and development efforts in oral drug delivery technologies.